Iron withdrawal strategies fail to prevent the growth of SiHa-induced tumors in mice

Gynecologic Oncology

Volumn 90, Issue 1, 2003, Pages 91-95

  Simonart, Thierry ^a   Boelaert, Johan R ^b   Andrei, Graciela ^c   De Clercq, Erik ^c   Snoeck, Robert ^a  

^a ERASME HOSPITAL   (Belgium)

^b General Hospital St Jan   (Belgium)

^c NONE

Author keywords

Deferiprone; Desferrioxamine

Indexed keywords

25 SD04; DEFERIPRONE; DEFEROXAMINE; FERRITIN; IRON; IRON CHELATE; STARCH; TRANSFERRIN; IRON CHELATING AGENT; PYRIDONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER GRAFT; CANCER GROWTH; CANCER INHIBITION; CONJUGATE; FEMALE; FERRITIN BLOOD LEVEL; HUMAN; HUMAN CELL; IRON BLOOD LEVEL; IRON OVERLOAD; IRON RESTRICTION; MALE; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TRANSFERRIN BLOOD LEVEL; TREATMENT FAILURE; UTERINE CERVIX CANCER; XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; CELL CULTURE; CELL DIVISION; DIET THERAPY; DRUG EFFECT; DRUG SCREENING; IRON INTAKE; PATHOLOGY; UTERINE CERVIX TUMOR;

ANIMALS; CELL DIVISION; DEFEROXAMINE; FEMALE; HUMANS; IRON CHELATING AGENTS; IRON, DIETARY; MICE; MICE, INBRED BALB C; MICE, NUDE; PYRIDONES; TUMOR CELLS, CULTURED; UTERINE CERVICAL NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0038500738     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-8258(03)00226-9     Document Type: Article

References (27)

1. zur Hausen H. Human papillomavirus in pathogenesis of anogenital cancer. Virology. 184:1991;9-13.
2. Schiffman M.H. Recent progress in defining the epidemiology of human papillomavirus infection and cervical neoplasia. J Natl Cancer Inst. 84:1992;394-397.
3. Rock C.L., Michael C.W., Reynolds R.K., Ruffin M.T. Prevention of cervix cancer. Crit Rev Oncol Hematol. 33:2000;169-185.
4. Thigpen J.T., Vance R., Puneky L., Khansur T. Chemotherapy as a palliative treatment in carcinoma of the uterine cervix. Semin Oncol. 22:(Suppl 3):1995;16-24.
5. Sitt J.A. High dose rate brachytherapy in the treatment of cervical carcinoma. Hematol Oncol Clin North Am. 13:1999;585-593.
6. Grisby P.W., Herzog T.J. Current management of patients with invasive cervical carcinoma. Clin Obstet Gynecol. 44:2001;531-537.
7. Weinberg E.D. Iron withholding a defense against viral infections . Biometals. 9:1996;393-399.
8. Boelaert J.R., Weinberg G.A., Weinberg E.D. Altered iron metabolism in HIV infection mechanisms, possible consequences, and proposals for management . Infect Agent Dis. 5:1996;36-46.
9. Sussman H.H. Iron in cancer. Pathobiology. 60:1992;2-9.
10. Weinberg E.D. The role of iron in cancer. Eur J Cancer Prev. 5:1996;19-36.
11. Simonart T., Boelaert J.R., Mosselmans R., Degraef C., Andrei G., Noel J.C., et al. Antiproliferative and apoptotic effects of iron chelators on human cervical carcinoma cells. Gynecol Oncol. 85:2002;95-102.
12. Davidson B., Goldberg I., Lerner-Geva L., Gotlieb W.H., Ben-Baruch G., Novikov I., et al. Expression of topoisomerase II and Ki-67 in cervical carcinoma-clinicopathological study using immunohistochemistry. APMIS. 108:2000;209-215.
13. Ho D.M., Hsu C.Y., Chiang H. MIB-1 labeling index as a prognostic indicator for survival in patients with FIGO stage IB squamous cell carcinoma of the cervix. Gynecol Oncol. 76:2000;97-102.
14. Andrei G., Snoeck R., Piette J., Delvenne P., De Clercq E. Inhibiting effects of cidofovir (HPMPC) on the growth of the human cervical carcinoma (SiHa) xenografts in athymic nude mice. Oncol Res. 10:1998;533-539.
15. Kontoghiorghes G.J. Dose response studies using desferrioxamine and orally active chelators in a mouse model. Scand J Haematol. 37:1986;63-70.
16. Mencacci A., Cenci E., Boelaert J.R., Bucci P., Mosci P., Fé d'Ostiani C., et al. Iron overload alters innate and T helper cell responses to Candida albicans in mice. J Infect Dis. 175:1997;1467-1476.
17. Hann H.W.L., Stahlhut M.W., Hann C.L. Effect of iron and desferioxamine on cell growth and in vitro ferritin synthesis in human hepatoma cell lines. Hepatology. 11:1990;566-569.
18. Brodie C., Siriwardana G., Lucas J., Schleicher R., Terada N., Szepesi A., et al. Neuroblastoma sensitivity to growth inhibition by desferrioxamine evidence for a block in G1 phase of the cell cycle . Cancer Res. 53:1993;3968-3975.
19. Richardson D., Ponka P., Baker E. The effect of the iron(III) chelator, desferrioxamine, on iron and tranferrin uptake by the human malignant melanoma cell. Cancer Res. 54:1994;685-689.
20. Haq R.U., Werely J.P., Chitambar C.R. Induction of apoptosis by iron deprivation in human leukemic CCRF-CEM cells. Exp Hematol. 23:1995;428-432.
21. Simonart T., Degraef C., Andrei G., Mosselmans R., Hermans P., Van Vooren J.P., et al. Iron chelators inhibit the growth and induce the apoptosis of Kaposi's sarcoma cells and of their putative endothelial precursors. J Invest Dermatol. 115:2000;893-900.
22. Hann H.W., Stahlut M.W., Rubin R., Maddrey W.C. Antitumour effect of deferoxamine on human hepatocellular carcinoma growing in athymic nude mice. Cancer. 70:1992;2051-2056.
23. Wang F., Elliott R.L., Head J.F. Inhibitory effect of deferoxamine mesylate and low iron diet on the 13762NF rat mammary adenocarcinoma. Anticancer Res. 19:1999;445-450.
24. Selig R.A., White L., Gramacho C., Sterling-Levis K., Fraser I.W., Naidoo D. Failure of iron chelators to reduce tumor growth in human neuroblastoma xenografts. Cancer Res. 58:1998;473-478.
25. Simonart T., Boelaert J.R., Andrei G., Degraef C., Hermans P., Noel J.C., et al. Desferrioxamine enhances AIDS-associated Kaposi's sarcoma tumor growth in xenograft model. Int J Cancer. 100:2002;140-143.
26. Gomes M.S., Dom G., Pedrosa J., Boelaert J.R., Appelberg R. Effects of iron deprivation on Mycobacterium avium growth. Tuber Lung Dis. 79:1999;321-328.
27. Gomes M.S., Boelaert J.R., Appelberg R. Role of iron in experimental Mycobacterium avium infection. J Clin Virol. 20:2001;117-122.